DURECT Corporation announced that the last patient has completed the study protocol in the Company's AHFIRM trial. AHFIRM is a Phase 2b randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of lasucosterol in subjects with severe alcohol-associated hepatitis (AH). A total of 301 patients were randomized and dosed in AHFIRM and DURECT plans to report topline data in the fourth quarter of 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.93 USD | -1.46% | -12.26% | +57.63% |
May. 14 | Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says | MT |
May. 13 | Transcript : DURECT Corporation, Q1 2024 Earnings Call, May 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.63% | 28.86M | |
+9.42% | 115B | |
+11.84% | 106B | |
-14.15% | 21.84B | |
-1.05% | 21.96B | |
-5.29% | 19.21B | |
-38.29% | 17.71B | |
-4.16% | 18.08B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- DRRX Stock
- News DURECT Corporation
- Durect Corporation Announces Last Patient Last Visit in Phase 2B Ahfirm Trial of Larsucosterol in Alcohol-Associated Hepatitis